Business Context and Reporting Period
This Form 8-K reports on the annual meeting of stockholders held by Denali Therapeutics Inc. on June 13, 2018. The company is incorporated in Delaware and is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
As of the record date (April 18, 2018), there were 94,441,782 shares of common stock outstanding. At the meeting, 52,534,211 shares (55.63%) were represented.
Director Elections (Class I)
Three nominees were elected to serve until the 2021 annual meeting:
- Douglas Cole, M.D.: 48,735,405 For; 2,142,814 Withheld; 1,655,992 Broker Non-Votes.
- Jay Flatley: 48,726,590 For; 2,151,629 Withheld; 1,655,992 Broker Non-Votes.
- Marc Tessier-Lavigne, Ph.D.: 47,868,568 For; 3,009,651 Withheld; 1,655,992 Broker Non-Votes.
Accounting Firm Ratification
Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- For: 52,494,996
- Against: 10,829
- Abstain: 28,386
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (94,441,782) and the percentage represented at the meeting (55.63%).
- Confirm the successful election of the three Class I directors and the specific vote counts for each.
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2018 fiscal year.
- Note that this filing contains no financial performance data; refer to the 10-K or 10-Q for financial metrics.